Premium
Therapeutic Impact of the Ethyl Acetate Extract of Tripterygium wilfordii Hook F on Nephritis in NZB/W F1 Mice
Author(s) -
Tao Xuelian c,
Fan Fred,
Hoffman Victoria,
Longo Nancy S,
Lipsky Peter E
Publication year - 2006
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.20.5.a1147-a
Subject(s) - tripterygium wilfordii , tripterygium , proteinuria , medicine , nephritis , antibody , lupus nephritis , immunology , therapeutic effect , kidney , glomerulonephritis , pharmacology , endocrinology , pathology , chemistry , disease , alternative medicine , glycoside , organic chemistry
This study was designed to examine the potential usage of the ethyl acetate (EA) extract of Tripterygium wilfordii Hook F (TwHF), a Chinese herbal medicine, in the treatment of systemic lupus erythematosus. A total of 48 twenty‐eight‐week old female NZB/W F1 mice were randomly divided into three groups and orally administered vehicle, the EA extract of TwHF at 18.25 mg/kg (EA low ) or 36.5mg/kg (EA high ), respectively, for 14 weeks. Proteinuria and serum anti‐ds‐DNA antibody titers were assayed before and after treatment. At the end of treatment, all animals were sacrificed and pathologic and Immunohistologic changes in the kidneys and spleens were examined by observers blinded to the treatment regimens. At 28 weeks of age, proteinuria (> 30mg/dL) and anti‐ds‐DNA antibody were found in all mice of the 3 groups without significant difference. At the end of treatment, the mean proteinuria of the EA low and EA high groups was significantly less than that of the vehicle group. Histological evidence of glomerulonephritis, glomerular deposition of IgG and complement 3 and cellular infiltration in the interstitium and perivascular regions were significantly less severe in the EA extract‐treated mice than in vehicle‐treated mice. Treatment with the EA extract significantly inhibited the progression of kidney disease in NZB/W F1 mice, though had no significant effect on the levels of anti‐dsDNA antibody.